Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Pfizer is doubling down on by spending $4.9 billion on the development-stage drugmaker Metsera.

The COVID-19 vaccine and treatment maker said early Monday that it will pay $47.50 per share in cash for each Metsera share. That represents a premium of more than 42% to Metsera’s closing price Friday.